234 related articles for article (PubMed ID: 24774503)
1. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases.
Blandizzi C; Gionchetti P; Armuzzi A; Caporali R; Chimenti S; Cimaz R; Cimino L; Lapadula G; Lionetti P; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Girolomoni G
Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):1-10. PubMed ID: 24774503
[TBL] [Abstract][Full Text] [Related]
2. anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.
Armuzzi A; Lionetti P; Blandizzi C; Caporali R; Chimenti S; Cimino L; Gionchetti P; Girolomoni G; Lapadula G; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Cimaz R
Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):11-32. PubMed ID: 24774504
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab in the treatment of immune-mediated diseases.
Lapadula G; Marchesoni A; Armuzzi A; Blandizzi C; Caporali R; Chimenti S; Cimaz R; Cimino L; Gionchetti P; Girolomoni G; Lionetti P; Marcellusi A; Mennini FS; Salvarani C
Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):33-48. PubMed ID: 24774505
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls.
Silva LC; Ortigosa LC; Benard G
Immunotherapy; 2010 Nov; 2(6):817-33. PubMed ID: 21091114
[TBL] [Abstract][Full Text] [Related]
5. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
Karampetsou MP; Liossis SN; Sfikakis PP
QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications.
Murdaca G; Colombo BM; Puppo F
Drugs Today (Barc); 2011 Apr; 47(4):277-88. PubMed ID: 21573251
[TBL] [Abstract][Full Text] [Related]
7. Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases.
Pereira R; Faria R; Lago P; Torres T
Curr Drug Saf; 2017; 12(3):162-170. PubMed ID: 28625143
[TBL] [Abstract][Full Text] [Related]
8. Sympathetic Nerve Hyperactivity in the Spleen: Causal for Nonpathogenic-Driven Chronic Immune-Mediated Inflammatory Diseases (IMIDs)?
Bellinger DL; Lorton D
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29652832
[TBL] [Abstract][Full Text] [Related]
9. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
10. Potential target of infliximab in autoimmune and inflammatory diseases.
Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
Licastro F; Chiappelli M; Ianni M; Porcellini E
Int J Immunopathol Pharmacol; 2009; 22(3):567-72. PubMed ID: 19822073
[TBL] [Abstract][Full Text] [Related]
12. [Immune-Mediated Inflammatory Diseases and accompanying comorbidities].
Majdan M
Wiad Lek; 2016; 69(4):611-615. PubMed ID: 27941197
[TBL] [Abstract][Full Text] [Related]
13. Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.
Pereira R; Lago P; Faria R; Torres T
Drug Dev Res; 2015 Dec; 76(8):419-27. PubMed ID: 26482111
[TBL] [Abstract][Full Text] [Related]
14. [Infliximab. Role in the treatment of psoriasis].
Mössner R; Reich K
Hautarzt; 2005 Sep; 56(9):831-2, 834-8. PubMed ID: 16133635
[TBL] [Abstract][Full Text] [Related]
15. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
Sfikakis PP
Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
Baker DE
Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
Isaacs JD; Cutolo M; Keystone EC; Park W; Braun J
J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.
Tracey D; Klareskog L; Sasso EH; Salfeld JG; Tak PP
Pharmacol Ther; 2008 Feb; 117(2):244-79. PubMed ID: 18155297
[TBL] [Abstract][Full Text] [Related]
20. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
